Thymogen Dosage Guide: Protocols, Calculator & Safety

Beginner Thymogen use typically follows Russian clinical practice conventions, adapted for self-administration. Thymogen's multi-route availability (intranasal, subcutaneous, oral) gives beginners more flexibility than most peptides.

Beginner intranasal protocol (most accessible, lowest barrier to entry):

• Dose: 50–100 mcg per nostril, once daily
• Route: intranasal drops or spray
• Course length: 10 days per cycle
• Frequency: 2–4 cycles per year, or during acute illness or infection exposure
• Timing: morning or as-needed at first sign of illness

Beginner subcutaneous protocol:

• Dose: 100 mcg per day (note: doses lower than most other peptides)
• Route: subcutaneous injection
• Course length: 10 days per cycle
• Frequency: 2–4 cycles per year
• Timing: morning, consistent time of day

Beginner first-cycle recommendations:

1. Source from a reputable supplier with certificate of analysis (purity ≥98%, correct molecular weight for Glu-Trp dipeptide ≈ 333.3 g/mol)
2. Consider intranasal route first for easier administration and immediate URI prevention benefit
3. Reconstitute according to standard peptide protocol (see reconstitution notes)
4. Start with a single cycle — 10 days — before committing to repeat cycles
5. Document effects — energy, subjective wellness, infection susceptibility, any side effects
6. Wait 60–90 days before repeat cycle

Common beginner use cases:

• Winter URI prevention: 10-day intranasal course at the start of cold/flu season, with optional repeat mid-season
• Pre-travel immune prep: 10-day course starting a week before international travel or exposure to unfamiliar environments
• Post-illness recovery: 10-day course after clearing an acute respiratory infection to support full immune recovery
• Perioperative immune support: 7–10 day course around elective surgery (coordinate with surgeon)
• Chronic stress / poor sleep recovery: 10-day course during or after extended periods of immune-challenging stress

What to expect:

• Effects are typically subtle — beginners often don't notice anything dramatic during the cycle
• The main reported benefit is reduced frequency or severity of URIs over the following 1–3 months
• Some users report modest improvements in energy or wellness
• No effect is common in healthy young adults with already robust immune function
• Effects are more noticeable in users with baseline immune challenges (frequent infections, immunosenescence, post-illness state)

Beginner supplies:

• Thymogen lyophilized powder (typically 1 mg vials)
• Bacteriostatic water for reconstitution
• Insulin syringes (29–31 gauge) if using subcutaneous
• Nasal spray bottle (pharmacy-grade) if using intranasal
• Alcohol swabs
• Sharps disposal container
• Subjective tracking log

Beginner dose calculation examples:

Intranasal at 100 mcg/nostril/day:

• Reconstitute 1 mg vial with 1 mL bacteriostatic water = 1 mg/mL = 100 mcg per 0.1 mL
• Draw 0.1 mL into nasal spray bottle or use drops; administer 50 mcg per nostril (0.05 mL each)
• Or reconstitute to 0.5 mg/mL (200 mcg/0.1 mL) and use 0.05 mL per nostril

Subcutaneous at 100 mcg/day:

• Reconstitute 1 mg vial with 1 mL bacteriostatic water = 1 mg/mL = 100 mcg per 0.1 mL (10 units on insulin syringe)
• Draw 10 units daily, inject subcutaneously

Beginner safety practices:

• Use fresh needles/droppers for each administration
• Keep reconstituted solution refrigerated; use within 30 days
• Rotate injection sites if using subcutaneous
• Clean nasal spray bottle components between cycles
• Stop immediately for any significant adverse reaction

What beginners often do wrong:

• Expecting dramatic acute effects. Thymogen is a subtle immune modulator; acute "feel-it" effects are uncommon.
• Using too high doses. Thymogen's effective dose range is low (50–100 mcg); higher doses don't add meaningful benefit.
• Continuous long-term dosing. The Khavinson framework uses pulsed dosing; long continuous dosing without breaks is not the prescribed pattern.
• Skipping the washout period. The 60–90 day break between cycles is part of the protocol, not an optional suggestion.
• Sourcing from unverified vendors. Peptide quality varies enormously; CoA documentation matters.

When to expand beyond beginner level:

• After 2–3 successful cycles with good tolerability
• With clear subjective or objective benefit (reduced infection rate, improved energy)
• With comfort in peptide handling and administration
• With interest in pairing with other Khavinson peptides or broader immune protocols

When to step back:

• No perceived benefit after 3 cycles
• Any side effects that don't resolve between cycles
• Autoimmune concerns or flares
• Change in medical circumstances that affect risk profile

Thymogen is one of the more approachable Khavinson peptides for beginners due to its intranasal availability, low dose, registered pharmaceutical status in Russia, and well-tolerated profile. For a first peptide in the Khavinson ecosystem, it is a reasonable choice.

Intermediate Thymogen users have completed several beginner cycles, are comfortable with administration, and typically want to refine dosing, extend protocols, and integrate Thymogen into broader immune and longevity stacks.

Intermediate dosing conventions:

• Intranasal: 100–200 mcg per nostril, once to twice daily
• Subcutaneous: 100 mcg daily (dose elevation above 100 mcg is generally not recommended — mechanism suggests threshold behavior rather than dose-response)
• Course length: 10–20 days per cycle
• Cycles per year: 4–6 (more frequent than beginner protocols for users with defined immune goals)
• Combination: intranasal during high-exposure periods plus subcutaneous during dedicated cycles

Intermediate use patterns:

Pattern A — Seasonal immune rotation:

• Fall (September-October): 10-day subcutaneous course, 100 mcg/day
• Winter intranasal (November-February): intranasal 100 mcg/nostril daily during high-infection-risk periods, as needed rather than continuous
• Spring (March-April): 10-day subcutaneous course
• Summer: maintenance without peptide; focus on sleep, nutrition, training

Pattern B — Khavinson quarterly rotation:

• Q1: Thymogen 10-day course + Pinealon 10-day course (overlapping)
• Q2: Epitalon 10-day course
• Q3: Thymogen 10-day course + Vilon 10-day course (overlapping)
• Q4: Cartalax or another tissue-specific peptide

Pattern C — Event-driven protocols:

• Pre-travel: 7-day intranasal course starting 1 week before travel, continuing during travel
• Pre-surgery: 10-day subcutaneous course starting 10 days before surgery, continuing post-op if clinically appropriate
• Post-illness: 10-day course after clearing infection to support full immune recovery
• Post-training block: 7-day course after heavy training or competition periods

Intermediate stacking:

• Thymogen + Thymalin — dual thymic peptide approach
• Thymogen + Thymosin alpha-1 — Russian + Western thymic peptides
• Thymogen + Pinealon + Epitalon — core Khavinson anti-aging stack
• Thymogen + BPC-157 — recovery-focused pairing
• Thymogen + KPV — immune + anti-inflammatory pairing

Intermediate monitoring:

• Before cycles: CBC with differential (lymphocyte subsets if available — CD4/CD8 ratio, NK cell count), hs-CRP, vitamin D, zinc, selenium
• During cycles: subjective tracking of energy, sleep, injection site response
• After cycles: infection rate tracking over following 3 months, subjective wellness
• Annual: full immune panel if accessible (CD3/CD4/CD8/CD19/CD56 subsets, immunoglobulin levels), vaccine response assessment if relevant

Intermediate dose adjustments:

• If no perceived benefit: consider verifying product purity, extending course to 15–20 days, adding intranasal to subcutaneous, or combining with Thymalin or Thymosin alpha-1
• If good response: maintain successful protocol; do not escalate unnecessarily
• If partial response: consider cycle frequency increase or combination approach
• If side effects emerge: reduce dose or route, evaluate vehicle/source quality, discontinue if persistent

Intermediate-level considerations:

Measuring immune response objectively:

• CBC with differential — simplest and most accessible; lymphocyte count trends are informative
• CD4/CD8 subsets — available in more comprehensive panels; Thymogen literature suggests trend improvement with adherent use
• NK cell activity or count — harder to access but relevant
• Immunoglobulin levels (IgG, IgA, IgM) — not typically changed by Thymogen specifically but useful baseline
• Vaccine response — if you get vaccines during or after a Thymogen cycle, titer response post-vaccination can serve as an indirect measure

Frequency and duration decisions:

• Users with frequent infections or chronic infectious states may run more frequent cycles
• Healthy users may find 2 cycles per year sufficient
• Older users with documented immunosenescence may benefit from quarterly cycles
• Acute-use protocols (pre-travel, pre-surgery) can be interspersed with cycling without concern for the structured quarterly schedule

Combined intranasal + subcutaneous approaches:

• Subcutaneous for systemic effect, intranasal for local URI prevention
• Run subcutaneous cycles quarterly plus intranasal during high-exposure periods
• Reasonable combination for intermediate users without concerns about excessive exposure

Intermediate stacking cautions:

• Don't combine Thymogen + Thymalin + Thymosin alpha-1 all simultaneously on first attempt; introduce sequentially to assess individual contributions
• If on any immune-modulating pharmacotherapy, coordinate timing with prescribing physician
• Monitor for autoimmune symptom emergence in users with family history or subclinical markers
• Maintain standard preventive care — vaccines, routine screening, approved antimicrobials for infections

When to consider advanced protocols:

• 3+ successful intermediate cycles with clear benefit
• Interest in biomarker-driven personalization
• Willingness to invest in more comprehensive lab monitoring
• Integration with broader longevity intervention stack (rapamycin, NAD+, hormone optimization)

When intermediate is the right stopping point:

• Good response with simple, sustainable protocol
• No need for additional complexity
• Financial or time constraints limiting more elaborate stacks
• Comfort with current level of self-management

Intermediate Thymogen users typically achieve the best cost-benefit ratio — enough cycling to capture meaningful benefit, without the complexity and expense of advanced multi-peptide stacks. This is a reasonable long-term maintenance level for many users.

Advanced Thymogen use involves multi-peptide immune optimization, integration with clinical monitoring, and coordination with broader longevity and immunosenescence intervention protocols. This level is appropriate for users with specific immune optimization goals, significant baseline immune concerns, or commitment to comprehensive gerontology-informed protocols.

Advanced dosing and combination patterns:

• Subcutaneous: 100–200 mcg daily
• Intranasal: 200–300 mcg per nostril twice daily during active cycles
• Combined routes: subcutaneous for systemic effect + intranasal for ongoing mucosal support
• Course length: 15–30 days per cycle
• Cycles per year: 6–8 for intensive immune optimization programs
• Combined with other thymic peptides: simultaneous or sequential Thymogen + Thymalin + Thymosin alpha-1

Advanced stack integration:

Comprehensive immune rejuvenation stack:

• Thymogen 100 mcg SC daily (20 days)
• Thymalin 10 mg IM every 3 days (during Thymogen cycle)
• Thymosin alpha-1 1.6 mg SC twice weekly (overlapping cycle)
• Vilon 100 mcg SC daily (5 days before Thymogen starts, overlapping)
• Foundation nutrients: vitamin D, zinc, selenium, omega-3, quercetin
• Lifestyle: optimized sleep, stress management, regular exercise

Integrated longevity and immune stack:

• Quarterly Thymogen cycles
• Epitalon quarterly cycles (opposite quarters from Thymogen)
• Pinealon quarterly cycles
• Continuous rapamycin biweekly dosing
• Continuous metformin daily dosing
• Continuous NAD+ precursors daily dosing
• GLP-1 agonists if metabolic indication
• Foundation nutrient support

Oncology adjunctive stack (specialist-managed):

• Thymogen perioperatively and during immunosuppression periods
• Coordinated with chemotherapy or radiation timing
• Combined with supportive BPC-157 and recovery peptides
• Always within integrative oncology framework, not in place of standard treatment

Advanced monitoring:

• Quarterly: CBC with full differential, comprehensive metabolic panel, hs-CRP, liver function, renal function
• Semi-annually: full immune panel (lymphocyte subsets, immunoglobulins, NK cell activity if available), vaccine titers for relevant vaccines, inflammaging markers (IL-6, TNF-alpha, homocysteine)
• Annually: lipid panel with particles, A1c, hormonal panel, tumor markers if age/risk-appropriate, comprehensive cancer screening, epigenetic age testing if engaged with that technology
• Ad hoc: response monitoring during acute illness, before/after vaccines, during periods of increased stress or exposure

Advanced biomarker-driven adjustments:

• Low CD4:CD8 ratio: favor Thymogen + Thymalin combined, extend cycle length
• Elevated hs-CRP: add anti-inflammatory peptides (KPV) or investigate underlying inflammation
• Reduced NK cell activity: maintain Thymogen cycles; consider adjunctive NK-supporting interventions
• Vaccine non-response or low titer: time Thymogen cycles around vaccination
• Frequent infections despite protocol: evaluate for underlying immunodeficiency with clinical immunology consultation

Advanced combination considerations:

• With hormone optimization: testosterone or estrogen replacement can affect immune function; coordinate timing
• With rapamycin: mTOR inhibition has immune effects; some evidence of immune rejuvenation with rapamycin alone; combined with Thymogen may be synergistic or additive
• With senolytic cycles: senolytic treatments (FOXO4-DRI, dasatinib/quercetin) may transiently reduce circulating senescent immune cells; timing with Thymogen cycles unclear but mechanistically complementary
• With peptide vaccines or immunotherapy: specialist coordination required

Advanced risk management:

• Autoimmune surveillance: annual autoimmune panel (ANA, thyroid antibodies, RF if indicated) to monitor for subclinical autoimmune emergence
• Malignancy surveillance: age-appropriate cancer screening on schedule; some evidence that immune rejuvenation supports tumor surveillance, but this is theoretical
• Infectious disease surveillance: annual TB screening if relevant, travel medicine updates as appropriate
• Injection site rotation: with multi-peptide protocols, site rotation becomes essential

Advanced cycle coordination:

• Don't start multiple new peptides in the same month — introduce sequentially
• Align peptide cycles with life events strategically (pre-travel, pre-surgery, post-acute illness)
• Build in rest periods — quarterly cycles with clear washouts, and consider an annual 1–2 month full peptide washout
• Document all interventions with dates for later attribution

Advanced population considerations:

• HIV or chronic viral infection: Thymogen is used adjunctively in Russian practice; specialist oversight essential; not a replacement for antiretroviral therapy
• Primary immunodeficiency: Thymogen may be adjunctive but does not replace immunoglobulin therapy or appropriate specialist management
• Elderly with documented immunosenescence: the primary target population; intensive cycling may be appropriate with monitoring
• Athletes with training-induced immunosuppression: intensive Thymogen cycling during heavy training or competition periods

Advanced decision points:

• Scale back if: biomarkers worsen, autoimmune emergence, no clear benefit despite adherent use, financial or time constraints
• Continue if: biomarkers stable or improving, subjective benefit, manageable protocol burden
• Expand if: specific unmet goals remain, willingness to accept additional complexity and cost, clear benefit from current protocol suggesting further optimization possible

Advanced considerations for longevity-focused users:

• Thymogen fits into the "immunosenescence intervention" layer of a comprehensive longevity protocol
• Effects on biological age markers (epigenetic clocks, inflammaging) are not well-characterized but theoretically plausible
• The broader Khavinson peptide rotation, with Thymogen included, represents one of the more comprehensive pharmacologic anti-aging frameworks available

The advanced summary: Thymogen at advanced levels is one component of a multi-peptide, multi-modality anti-aging and immune optimization protocol. It is typically part of a rotation rather than a standalone, and it works best when foundational immune supports (vitamin D, zinc, selenium, sleep, exercise, stress management) are also optimized. For users committed to this level of engagement with longevity pharmacology, Thymogen represents one of the better-validated Khavinson peptides to include.